ATP5F1D

Across TCGA pan-cancer cohorts, ATP5F1D Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ATP5F1D data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ATP5F1D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5F1D expression acts as an unfavorable survival marker.

BLCA are the cancer types where ATP5F1D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.166	0.625	.020	15	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ATP5F1D–BLCA (DFS)

Open the BLCA breakdown →